Lonza Group AG
LZAGY · OTC
Company research
Lonza Group AG (OTC: LZAGY) is a Swiss multinational and the world's largest pure-play contract development and manufacturing organization (CDMO), headquartered in Basel, Switzerland, and founded in 1897. The company serves the global pharmaceutical, biotechnology, and healthcare industries, offering integrated development and manufacturing services across four core segments: Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients. With a global workforce of approximately 18,500 employees across more than 30 sites on five continents, Lonza generates revenues of approximately CHF 6.72 billion (2023) and holds a market capitalization of approximately USD 51.7 billion. Led by CEO Wolfgang Wienand, Lonza continues to expand its capabilities — including a recent agreement to acquire a large-scale biologics site in Vacaville, U.S., from Roche — reinforcing its position as a pioneer and market leader in the CDMO industry.
Research reports
Extensive independent report framing Lonza as a geopolitically “safe‑haven” pure‑play CDMO compounder with scarce large‑scale biologics capacity, benefiting from outsourcing trends and the U.S. Biosecure Act but trading at premium valuation multiples that require near‑flawless execution. It emphasizes the “One Lonza” transformation, Vacaville acquisition, CDMO growth model and scenario analysis through 2030, while highlighting key risks around CHI divestment execution, capex intensity, potential overcapacity, and sustained weakness in early‑stage biotech funding.
DBS Group Research (DBS Bank) · September 18, 2025EUROPE EQUITY RESEARCH – LonzaInstitutional equity research note on Lonza (LONN SW) with a BUY rating and CHF690 12‑month target price, based on a 36.9x 2025F P/E (0.2 standard deviations above its five‑year average) and strong H1 2025 results driven by c.23% CDMO sales growth, margin expansion and robust free cash flow. The thesis focuses on Lonza’s global leadership in biologics CDMO, upgraded 2025 CDMO guidance (20–21% sales growth and 30–31% core EBITDA margin), and positioning to ride ADC and cell‑and‑gene uptrends, while flagging risks from higher European cost structure, currency volatility, raw‑material and supply‑chain pressures, and lower forecast EPS CAGR versus key competitor Samsung Biologics.